Company: Boehringer Ingelheim RCV GmbH & Co KG
Job title: Head of Cancer Pharmacology and Disease Positioning
Mark Petronczki currently heads the Department of Cancer Pharmacology and Disease Position at Boehringer Ingelheim. The Department advances drug discovery programs of BI’s cancer cell-directed portfolio and supports clinical stage programs with in vivo pharmacology studies. In addition, Mark leads collaborations of BI with external partners and acts as the Austrian coordinator of the company’s Discovery Research global post-doc program. Previously, Mark headed a group of laboratories pursuing new therapeutic concepts and early-stage drug discovery programs in oncology. Before joining BI in 2014, Mark led a research group at the Cancer Research UK London Research Institute (now part of the Francis Crick Institute) with a focus on cell division and genome instability. Between 2000 and 2007, he completed his PhD and postdoc at the Research Institute of Molecular Pathology (Vienna, Austria) in the laboratories of Kim Nasmyth and Jan-Michael Peters, respectively. Mark is part of the EMBO Young Investigator network.
Addressing EGFR Mutation-Driven Resistance Using Next-Generation EGFR Inhibitors 9:40 am
• EGFR resistance mutations limit the clinical impact of approved tyrosine kinase inhibitors in EGFR-mutated NSCLC • Discovery and characterization of EGFR wild-type sparing inhibitors with potent activity against the two major EGFR resistance mutations T790M and C797S • Next generation EGFR inhibitors prevent and tackle resistance mutations arising upon treatment with approved EGFR inhibitorsRead more
day: Day One